Protein Mapping Method Could Show How Drugs Move Through Tissue

A new way to see a drug’s biological neighborhood

Researchers at the University at Buffalo have developed a spatial-proteomics method designed to show where thousands of proteins are distributed across an entire tissue section—and where a treatment sits among them. The technique, called hexagonal micro-scaffold assisted spatial proteomics, or hex-MASP, could give drug researchers a more detailed way to study whether a therapy reaches the tissue regions where it is meant to act and how those regions respond.

The work was reported in the Proceedings of the National Academy of Sciences. Its central result is a type of tissue map that the researchers compare with a satellite view: instead of offering a limited snapshot of a few biological markers, the approach aims to build many high-detail maps across a larger biological landscape.

In a demonstration using mouse brain tissue treated with monoclonal antibodies, the team produced maps of the therapeutic antibodies alongside more than 6,000 brain proteins across whole tissue sections. That pairing is significant because a drug’s presence in an organ does not necessarily mean it reaches every relevant region evenly.

Why location matters in drug development

Many medicines are evaluated through measurements that summarize an organ or tissue as a whole. Those measurements can be useful, but they may miss local differences. A treatment can enter an organ unevenly; proteins associated with disease may be concentrated in particular regions; and the tissue response may vary from place to place.

Jun Qu, a professor of pharmaceutical sciences at the University at Buffalo who developed the technology with his team, said that viewing thousands of protein maps together could help researchers investigate how disease and treatment reshape tissue. The intended use is not simply to make prettier images. By linking a drug’s location to the distributions of many proteins, researchers may be able to identify possible therapeutic targets and learn more about why a treatment succeeds in one part of a tissue but not another.

The method addresses a practical problem for therapies such as monoclonal antibodies, which are designed to bind specific protein targets. Researchers need to understand not only whether an antibody enters an organ, but also whether it reaches the right microenvironments and what changes occur around those locations.

How hex-MASP is meant to work

Hex-MASP is short for hexagonal micro-scaffold assisted spatial proteomics. The technique is designed to generate protein-distribution information with higher spatial resolution, robustness and throughput than earlier versions of the pipeline, according to the researchers.

Spatial proteomics combines two demanding goals: identifying proteins and retaining information about where those proteins came from in a tissue. Conventional protein analysis often requires homogenizing a sample, which can erase the spatial organization that is biologically important. A spatial approach seeks to preserve that organization so researchers can compare regions within the same slice of tissue.

In the reported mouse-brain experiment, the method captured the distribution of administered therapeutic antibodies and thousands of endogenous proteins. The result is a data-rich map that can connect a drug’s route through tissue with the protein environment it encounters.

Potential uses—and an important limitation

The researchers say the technology could help guide development of safer and more effective medicines. It may be useful for examining whether a candidate drug reaches its intended tissue region, finding local protein patterns associated with a treatment response, and investigating potential off-target effects suggested by changes elsewhere in the tissue.

It could also support research in diseases where location is central to biology, including disorders of the brain and conditions that create distinct tissue microenvironments. The method’s ability to map a therapy and a large set of proteins together is the key feature: it turns drug distribution and tissue biology into related measurements rather than separate experiments.

Still, the reported application was a mouse-brain study. The source describes a promising research platform, not a validated clinical diagnostic or a proven way to improve a specific human therapy. Translating a complex laboratory workflow into routine use will require continued work on reproducibility, cost, sample handling and the interpretation of very large datasets.

From a tissue snapshot to a broader biological map

The larger promise of hex-MASP is that it could make pharmaceutical research more spatially informed. If a therapy’s effects are uneven within an organ, averages can conceal the information needed to explain that unevenness. A map that tracks both the treatment and thousands of proteins may reveal patterns that simpler measurements cannot.

For drug developers, that could influence decisions much earlier in the research process: which targets to pursue, which molecular formats to use, how to interpret an apparent nonresponse, and where to look for unintended biological effects. The University at Buffalo team’s demonstration does not settle those questions, but it offers a technical route for asking them with much greater detail.

The work illustrates a broader shift in biomedical measurement. Rather than treating tissue as a uniform sample, researchers are increasingly trying to understand it as an organized landscape. Tools that can map many proteins at once may help make that landscape visible—and make drug development more responsive to the biology of place.

This article is based on reporting by Medical Xpress. Read the original article.